| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors A Carr, K Samaras, S Burton, M Law, J Freund, DJ Chisholm, DA Cooper Aids 12 (7), F51-F58, 1998 | 3019 | 1998 |
| Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial ME Hannah, WJ Hannah, SA Hewson, ED Hodnett, S Saigal, AR Willan The Lancet 356 (9239), 1375-1383, 2000 | 2639 | 2000 |
| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2117 | 2003 |
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study A Carr, K Samaras, A Thorisdottir, GR Kaufmann, DJ Chisholm, ... The Lancet 353 (9170), 2093-2099, 1999 | 1915 | 1999 |
| Adverse effects of antiretroviral therapy A Carr, DA Cooper The Lancet 356 (9239), 1423-1430, 2000 | 1553 | 2000 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1501 | 2006 |
| Cardiovascular risk and body-fat abnormalities in HIV-infected adults S Grinspoon, A Carr New England Journal of Medicine 352 (1), 48-62, 2005 | 1402 | 2005 |
| Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance A Carr, K Samaras, DJ Chisholm, DA Cooper The Lancet 351 (9119), 1881-1883, 1998 | 1359 | 1998 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1174 | 2008 |
| A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome A Carr, J Miller, M Law, DA Cooper Aids 14 (3), F25-F32, 2000 | 785 | 2000 |
| A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease SA Danner, A Carr, JM Leonard, LM Lehman, F Gudiol, J Gonzales, ... New England Journal of Medicine 333 (23), 1528-1534, 1995 | 688 | 1995 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 578 | 2008 |
| An objective case definition of lipodystrophy in HIV-infected adults: a case-control study A Carr The Lancet 361 (9359), 726-735, 2003 | 577 | 2003 |
| Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel M Schambelan, CA Benson, A Carr, JS Currier, MP Dubé, JG Gerber, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 31 (3), 257-275, 2002 | 561 | 2002 |
| Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission T Zhu, N Wang, A Carr, DS Nam, R Moor-Jankowski, DA Cooper, DD Ho Journal of virology 70 (5), 3098-3107, 1996 | 547 | 1996 |
| Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy JS Currier, JD Lundgren, A Carr, D Klein, CA Sabin, PE Sax, JT Schouten, ... Circulation 118 (2), e29-e35, 2008 | 455 | 2008 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 447 | 2010 |
| Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III … K Samaras, H Wand, M Law, S Emery, D Cooper, A Carr Diabetes care 30 (1), 113-119, 2007 | 418 | 2007 |
| Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy PWG Mallon, J Miller, DA Cooper, A Carr Aids 17 (7), 971-979, 2003 | 418 | 2003 |
| Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy A Carr, D Marriott, A Field, E Vasak, DA Cooper The Lancet 351 (9098), 256-261, 1998 | 413 | 1998 |
